Global Rotavirus Prophylaxis Market, By Treatment (Rotavac, Rotarix, Rotavin-M1 and Others), By Route of Administration (Oral, Parenteral and Others), By End-user (Hospital, Homecare, Specialty centers and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

The rotavirus vaccine protects against rotavirus infections, which are the most common cause of severe diarrhoea in young children. Severe diarrhoea, vomiting, fever, and abdominal pain are all symptoms of rotavirus infection, which can lead to illness. The rotavirus vaccine is given orally in two or three doses beginning around the age of six weeks. Rotavirus is a Reoviridae virus with a double-stranded RNA genome that is transmitted by the faecal-oral route. It causes gastroenteritis by infecting the cell lining of the small intestine. Rotavirus sickness was a substantial health issue among children in both industrialized and developing countries prior to the arrival of rotavirus vaccines on the market.

Impact of Covid-19 pandemic on market

Clinical research battled with how to best keep participants safe from a new infectious disease as COVID-19 spread around the globe. The global health community has learnt what works to reduce COVID-19 risk during the last year, and new vaccines are progressively becoming available to countries to prevent COVID-19.

Growth in business operations by emerging and small sized players

The rising frequency of rotavirus infection among children is a primary driver of the market, since it increases demand for rotavirus vaccines. The high frequency of rotavirus, as well as increased patient awareness and government initiatives, are driving the worldwide rotavirus prophylaxis market. Furthermore, advancements in the pharmaceutical and biotechnology sectors or industries, as well as an increase in vaccination demand, are some of the driving reasons for market expansion. Nonetheless, restricted income prospects, high treatment costs, and the scientific challenge of creating vaccines are some of the major challenges limiting the market's growth.

The global Rotavirus prophylaxis market is segmented based on treatment, route of administration, end-user, and region.

On the basis of Treatment, the global Rotavirus prophylaxis market is segmented into Rotavac, Rotarix, Rotavin-M1 and Others. Based on Route of administration, the target market is segmented into Oral, Parenteral and Others. On the basis of End-user, the target market is segmented into Hospital, Homecare, Specialty centers and Others.

Regional Insights:

On region the global Rotavirus Prophylaxis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to hold the largest market share for global rotavirus prophylaxis market. This is mainly because of the established regulatory framework, strong demand for disease-specific therapy, refined healthcare infrastructure, and greater patient awareness, as well as the high prevalence of rotavirus. Because of the existence of worldwide marketed players and the increase in population, Europe is considered the second fastest growing regional segment.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Rotavirus prophylaxis market report based on treatment, route of administration, end-user, and region.

Global Rotavirus Prophylaxis Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the global Rotavirus prophylaxis market includes Lanzhou Institute of Biologicals Products Co., Ltd, QIMR Berghofer Medical Research Institute, BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, GlaxoSmithKline plc, Sanofi and Others.

• GlaxoSmithKline Plc,.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Lanzhou Institute of Biologicals Products Co., Ltd
• QIMR Berghofer Medical Research Institute
• BIOVIRx Inc.
• Serum Institute of India Pvt. Ltd.
• Merck & Co., Inc.
• Bharat Biotech
• Sanofi
• Others.

“*” marked represents similar segmentation in other categories in the respective section